drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06655 | DB09381 | 5 | 192 | [
"DDInter1077",
"DDInter678"
] | Liraglutide | Esterified estrogens | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
5,
24,
192
]
],
[
[
5,
24,
1019
],
[
1019,
63,
192
]
],
[
[
5,
63,
1685
],
[
1685,
24,
192
]
],
[
[
5,
24,
1040
],
[
1040,
24,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin... |
DB00227 | DB13874 | 1,463 | 1,501 | [
"DDInter1098",
"DDInter639"
] | Lovastatin | Enasidenib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1463,
24,
1501
]
],
[
[
1463,
24,
663
],
[
663,
24,
1501
]
],
[
[
1463,
25,
1604
],
[
1604,
24,
1501
]
],
[
[
1463,
40,
681
],
[
681,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lovastatin may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may ca... |
DB00580 | DB00673 | 311 | 723 | [
"DDInter1910",
"DDInter112"
] | Valdecoxib | Aprepitant | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
311,
24,
723
]
],
[
[
311,
24,
214
],
[
214,
63,
723
]
],
[
[
311,
63,
600
],
[
600,
24,
723
]
],
[
[
311,
25,
629
],
[
629,
63,... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and F... |
DB01233 | DB09472 | 1,311 | 1,383 | [
"DDInter1197",
"DDInter1693"
] | Metoclopramide | Sodium sulfate | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1311,
24,
1383
]
],
[
[
1311,
62,
1252
],
[
1252,
23,
1383
]
],
[
[
1311,
64,
146
],
[
146,
24,
1383
]
],
[
[
1311,
24,
643
],
[
643,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
... | Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Metoclopramide may lead to a major life threatening interaction when taken with Propiomazine and Propiomazine may ... |
DB00312 | DB12141 | 1,023 | 971 | [
"DDInter1423",
"DDInter817"
] | Pentobarbital | Gilteritinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1023,
24,
971
]
],
[
[
1023,
24,
1135
],
[
1135,
23,
971
]
],
[
[
1023,
24,
466
],
[
466,
62,
971
]
],
[
[
1023,
24,
820
],
[
820,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and ... |
DB06595 | DB12130 | 1,491 | 1,017 | [
"DDInter1214",
"DDInter1094"
] | Midostaurin | Lorlatinib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1491,
24,
1017
]
],
[
[
1491,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1491,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1491,
63,
590
],
[
590... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
DB00432 | DB14783 | 1,083 | 287 | [
"DDInter1868",
"DDInter574"
] | Trifluridine | Diroximel fumarate | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1083,
24,
287
]
],
[
[
1083,
24,
384
],
[
384,
24,
287
]
],
[
[
1083,
63,
599
],
[
599,
24,
287
]
],
[
[
1083,
40,
1238
],
[
1238,
... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzum... |
DB00467 | DB09045 | 1,467 | 52 | [
"DDInter644",
"DDInter607"
] | Enoxacin | Dulaglutide | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1467,
24,
52
]
],
[
[
1467,
24,
170
],
[
170,
23,
52
]
],
[
[
1467,
25,
870
],
[
870,
24,
52
]
],
[
[
1467,
40,
1299
],
[
1299,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may... |
DB00238 | DB00518 | 188 | 510 | [
"DDInter1285",
"DDInter35"
] | Nevirapine | Albendazole | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Moderate | 1 | [
[
[
188,
24,
510
]
],
[
[
188,
6,
7950
],
[
7950,
45,
510
]
],
[
[
188,
21,
28680
],
[
28680,
60,
510
]
],
[
[
188,
24,
1220
],
[
1220,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Nevirapine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Albendazole (Compound)
Nevirapine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Albendazole (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexametha... |
DB00382 | DB00424 | 62 | 19 | [
"DDInter1734",
"DDInter896"
] | Tacrine | Hyoscyamine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Moderate | 1 | [
[
[
62,
24,
19
]
],
[
[
62,
24,
1166
],
[
1166,
1,
19
]
],
[
[
62,
24,
85
],
[
85,
63,
19
]
],
[
[
62,
63,
701
],
[
701,
24,
1... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
],
[
"... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron (Compound) resembles Hyoscyamine (Compound)
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerba... |
DB00029 | DB00749 | 25 | 59 | [
"DDInter99",
"DDInter699"
] | Anistreplase | Etodolac | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
25,
24,
59
]
],
[
[
25,
24,
1018
],
[
1018,
24,
59
]
],
[
[
25,
24,
848
],
[
848,
63,
59
]
],
[
[
25,
64,
1578
],
[
1578,
24,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibu... |
DB00468 | DB06702 | 1,424 | 573 | [
"DDInter1557",
"DDInter731"
] | Quinine | Fesoterodine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1424,
24,
573
]
],
[
[
1424,
23,
211
],
[
211,
1,
573
]
],
[
[
1424,
64,
494
],
[
494,
1,
573
]
],
[
[
1424,
6,
12523
],
[
12523,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[
"... | Quinine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Quinine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Quinine (Comp... |
DB00191 | DB01170 | 73 | 1,150 | [
"DDInter1447",
"DDInter846"
] | Phentermine | Guanethidine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
73,
24,
1150
]
],
[
[
73,
6,
7390
],
[
7390,
45,
1150
]
],
[
[
73,
24,
1445
],
[
1445,
24,
1150
]
],
[
[
73,
24,
1344
],
[
1344,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compoun... | Phentermine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Guanethidine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Ph... |
DB04865 | DB14711 | 4 | 779 | [
"DDInter1335",
"DDInter1680"
] | Omacetaxine mepesuccinate | Smallpox (Vaccinia) Vaccine, Live | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
4,
25,
779
]
],
[
[
4,
64,
1064
],
[
1064,
25,
779
]
],
[
[
4,
24,
478
],
[
478,
25,
779
]
],
[
[
4,
63,
147
],
[
147,
25,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clad... | Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00745 | DB14723 | 307 | 159 | [
"DDInter1236",
"DDInter1026"
] | Modafinil | Larotrectinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
307,
24,
159
]
],
[
[
307,
24,
466
],
[
466,
23,
159
]
],
[
[
307,
23,
1135
],
[
1135,
23,
159
]
],
[
[
307,
24,
741
],
[
741,
2... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxe... |
DB00436 | DB09043 | 323 | 135 | [
"DDInter179",
"DDInter36"
] | Bendroflumethiazide | Albiglutide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
323,
24,
135
]
],
[
[
323,
23,
126
],
[
126,
23,
135
]
],
[
[
323,
63,
1647
],
[
1647,
23,
135
]
],
[
[
323,
24,
870
],
[
870,
2... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
... | Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose a... |
DB00252 | DB00434 | 362 | 13 | [
"DDInter1460",
"DDInter459"
] | Phenytoin | Cyproheptadine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
362,
24,
13
]
],
[
[
362,
24,
104
],
[
104,
63,
13
]
],
[
[
362,
1,
11305
],
[
11305,
1,
13
]
],
[
[
362,
1,
1236
],
[
1236,
63,... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Phenytoin (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Cyproheptadine... |
DB00808 | DB09038 | 1,605 | 1,450 | [
"DDInter916",
"DDInter636"
] | Indapamide | Empagliflozin | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1605,
24,
1450
]
],
[
[
1605,
24,
659
],
[
659,
63,
1450
]
],
[
[
1605,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1605,
24,
1486
],
[
1486... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and T... |
DB00612 | DB01268 | 1,121 | 1,151 | [
"DDInter216",
"DDInter1731"
] | Bisoprolol | Sunitinib | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1121,
24,
1151
]
],
[
[
1121,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
1121,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
1121,
24,
1148
],
[
1... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bisoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bisoprolol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Bisoprolol (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB00641 | DB01097 | 467 | 1,377 | [
"DDInter1675",
"DDInter1033"
] | Simvastatin | Leflunomide | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
467,
25,
1377
]
],
[
[
467,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
467,
18,
2049
],
[
2049,
57,
1377
]
],
[
[
467,
21,
28864
],
[
28864,... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lefl... | Simvastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Simvastatin (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound)
Simvastatin (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused ... |
DB00549 | DB01073 | 522 | 1,488 | [
"DDInter1955",
"DDInter745"
] | Zafirlukast | Fludarabine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
522,
24,
1488
]
],
[
[
522,
24,
372
],
[
372,
1,
1488
]
],
[
[
522,
21,
28701
],
[
28701,
60,
1488
]
],
[
[
522,
24,
975
],
[
975,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Zafirlukast (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound)
Zafirlukast may cause a moderate int... |
DB00816 | DB00880 | 1,674 | 359 | [
"DDInter1346",
"DDInter360"
] | Orciprenaline | Chlorothiazide | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
1674,
24,
359
]
],
[
[
1674,
63,
1577
],
[
1577,
1,
359
]
],
[
[
1674,
24,
504
],
[
504,
1,
359
]
],
[
[
1674,
21,
28762
],
[
28762,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazid... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide... |
DB00731 | DB00795 | 1,144 | 50 | [
"DDInter1269",
"DDInter1725"
] | Nateglinide | Sulfasalazine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
1144,
24,
50
]
],
[
[
1144,
24,
712
],
[
712,
1,
50
]
],
[
[
1144,
63,
161
],
[
161,
1,
50
]
],
[
[
1144,
6,
7524
],
[
7524,
45,... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine... |
DB00222 | DB00867 | 245 | 1,052 | [
"DDInter825",
"DDInter1606"
] | Glimepiride | Ritodrine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
245,
24,
1052
]
],
[
[
245,
24,
532
],
[
532,
40,
1052
]
],
[
[
245,
24,
870
],
[
870,
23,
1052
]
],
[
[
245,
24,
708
],
[
708,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Ritodrine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction th... |
DB08820 | DB09074 | 1,478 | 1,362 | [
"DDInter997",
"DDInter1327"
] | Ivacaftor | Olaparib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1478,
24,
1362
]
],
[
[
1478,
24,
627
],
[
627,
63,
1362
]
],
[
[
1478,
63,
896
],
[
896,
24,
1362
]
],
[
[
1478,
24,
1313
],
[
1313,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide... |
DB01132 | DB01224 | 1,130 | 623 | [
"DDInter1472",
"DDInter1553"
] | Pioglitazone | Quetiapine | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1130,
24,
623
]
],
[
[
1130,
24,
851
],
[
851,
1,
623
]
],
[
[
1130,
63,
695
],
[
695,
1,
623
]
],
[
[
1130,
6,
12523
],
[
12523,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound... |
DB00188 | DB09122 | 168 | 1,613 | [
"DDInter222",
"DDInter1409"
] | Bortezomib | Peginterferon beta-1a | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
168,
24,
1613
]
],
[
[
168,
24,
671
],
[
671,
24,
1613
]
],
[
[
168,
23,
152
],
[
152,
24,
1613
]
],
[
[
168,
24,
1155
],
[
1155,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bosentan a... |
DB00686 | DB01254 | 383 | 1,213 | [
"DDInter1424",
"DDInter484"
] | Pentosan polysulfate | Dasatinib | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
383,
24,
1213
]
],
[
[
383,
21,
28845
],
[
28845,
60,
1213
]
],
[
[
383,
24,
283
],
[
283,
63,
1213
]
],
[
[
383,
24,
1226
],
[
1226,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Pentosan polysulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Ef... | Pentosan polysulfate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Dasatinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken... |
DB00193 | DB11113 | 534 | 657 | [
"DDInter1841",
"DDInter307"
] | Tramadol | Castor oil | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
534,
24,
657
]
],
[
[
534,
24,
927
],
[
927,
63,
657
]
],
[
[
534,
24,
1491
],
[
1491,
24,
657
]
],
[
[
534,
25,
985
],
[
985,
2... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midosta... |
DB00556 | DB01268 | 1,262 | 1,151 | [
"DDInter1429",
"DDInter1731"
] | Perflutren | Sunitinib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1262,
24,
1151
]
],
[
[
1262,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
1262,
23,
112
],
[
112,
23,
1151
]
],
[
[
1262,
24,
1148
],
[
11... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Menopausal symptoms"
],
[
"Menopausal symptoms",
"{u} (S... | Perflutren (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects wh... |
DB00704 | DB08870 | 267 | 850 | [
"DDInter1263",
"DDInter228"
] | Naltrexone | Brentuximab vedotin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
267,
24,
850
]
],
[
[
267,
24,
788
],
[
788,
24,
850
]
],
[
[
267,
63,
1570
],
[
1570,
24,
850
]
],
[
[
267,
24,
1583
],
[
1583,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Azithrom... |
DB00095 | DB00851 | 66 | 611 | [
"DDInter623",
"DDInter463"
] | Efalizumab | Dacarbazine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
66,
24,
611
]
],
[
[
66,
24,
141
],
[
141,
24,
611
]
],
[
[
66,
24,
850
],
[
850,
63,
611
]
],
[
[
66,
63,
305
],
[
305,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedoti... |
DB00619 | DB04835 | 1,419 | 1,655 | [
"DDInter909",
"DDInter1125"
] | Imatinib | Maraviroc | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
1419,
24,
1655
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
1419,
18,
7247
],
[
7247,
57,
1655
]
],
[
[
1419,
21,
28792
],
[
28... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Imatinib (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Maraviroc (Compound)
Imatinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by ... |
DB08899 | DB11979 | 129 | 1,320 | [
"DDInter649",
"DDInter625"
] | Enzalutamide | Elagolix | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
129,
24,
1320
]
],
[
[
129,
64,
168
],
[
168,
23,
1320
]
],
[
[
129,
62,
608
],
[
608,
23,
1320
]
],
[
[
129,
25,
1612
],
[
1612,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezom... | Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a mi... |
DB00624 | DB01067 | 1,561 | 959 | [
"DDInter1775",
"DDInter826"
] | Testosterone | Glipizide | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1561,
24,
959
]
],
[
[
1561,
63,
245
],
[
245,
40,
959
]
],
[
[
1561,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1561,
6,
8374
],
[
8374,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB04946 | DB08824 | 924 | 591 | [
"DDInter907",
"DDInter959"
] | Iloperidone | Ioflupane I-123 | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
924,
24,
591
]
],
[
[
924,
21,
28722
],
[
28722,
60,
591
]
],
[
[
924,
40,
1664
],
[
1664,
24,
591
]
],
[
[
924,
64,
401
],
[
401,
... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Iloperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is cau... | Iloperidone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ioflupane I-123 (Compound)
Iloperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Iloperidone may lead to a major life... |
DB01254 | DB12332 | 1,213 | 1,619 | [
"DDInter484",
"DDInter1626"
] | Dasatinib | Rucaparib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1213,
24,
1619
]
],
[
[
1213,
63,
222
],
[
222,
23,
1619
]
],
[
[
1213,
23,
271
],
[
271,
23,
1619
]
],
[
[
1213,
62,
112
],
[
112,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron ... |
DB00445 | DB09039 | 322 | 1,670 | [
"DDInter655",
"DDInter629"
] | Epirubicin | Eliglustat | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
322,
24,
1670
]
],
[
[
322,
24,
479
],
[
479,
23,
1670
]
],
[
[
322,
24,
1164
],
[
1164,
24,
1670
]
],
[
[
322,
64,
839
],
[
839,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipra... |
DB00697 | DB05812 | 876 | 1,374 | [
"DDInter1821",
"DDInter8"
] | Tizanidine | Abiraterone | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
876,
24,
1374
]
],
[
[
876,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
876,
23,
112
],
[
112,
23,
1374
]
],
[
[
876,
63,
1494
],
[
1494,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Tizanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effect) ... | Tizanidine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken wit... |
DB00777 | DB01067 | 146 | 959 | [
"DDInter1537",
"DDInter826"
] | Propiomazine | Glipizide | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
146,
24,
959
]
],
[
[
146,
63,
245
],
[
245,
40,
959
]
],
[
[
146,
24,
1411
],
[
1411,
1,
959
]
],
[
[
146,
24,
22
],
[
22,
63,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00745 | DB06335 | 307 | 761 | [
"DDInter1236",
"DDInter1646"
] | Modafinil | Saxagliptin | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Minor | 0 | [
[
[
307,
23,
761
]
],
[
[
307,
6,
7524
],
[
7524,
45,
761
]
],
[
[
307,
21,
29226
],
[
29226,
60,
761
]
],
[
[
307,
24,
1491
],
[
1491,
... | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Modafinil (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Saxagliptin (Compound)
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB01284 | DB10315 | 1,042 | 1,137 | [
"DDInter1782",
"DDInter1127"
] | Tetracosactide | Measles virus vaccine live attenuated | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Moderate | 1 | [
[
[
1042,
24,
1137
]
],
[
[
1042,
64,
581
],
[
581,
25,
1137
]
],
[
[
1042,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
1042,
25,
676
],
[
676,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Tetracosactide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Inflixi... | Tetracosactide may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Ana... |
DB00489 | DB00731 | 17 | 1,144 | [
"DDInter1704",
"DDInter1269"
] | Sotalol | Nateglinide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
17,
24,
1144
]
],
[
[
17,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
17,
25,
609
],
[
609,
63,
1144
]
],
[
[
17,
62,
542
],
[
542,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused ... | Sotalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Sotalol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Sotal... |
DB09122 | DB11652 | 1,613 | 1,155 | [
"DDInter1409",
"DDInter1891"
] | Peginterferon beta-1a | Tucatinib | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1613,
24,
1155
]
],
[
[
1613,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1613,
63,
609
],
[
609,
24,
1155
]
],
[
[
1613,
24,
1320
],
[
1320... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexaro... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cl... |
DB00041 | DB01227 | 1,648 | 1,301 | [
"DDInter38",
"DDInter1043"
] | Aldesleukin | Levacetylmethadol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1648,
24,
1301
]
],
[
[
1648,
24,
675
],
[
675,
1,
1301
]
],
[
[
1648,
24,
1242
],
[
1242,
24,
1301
]
],
[
[
1648,
24,
516
],
[
516,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a modera... |
DB00035 | DB00812 | 1,314 | 998 | [
"DDInter507",
"DDInter1451"
] | Desmopressin | Phenylbutazone | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
1314,
24,
998
]
],
[
[
1314,
24,
576
],
[
576,
1,
998
]
],
[
[
1314,
24,
704
],
[
704,
40,
998
]
],
[
[
1314,
6,
7720
],
[
7720,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Phenylbutazone (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Phenylbutazone (Comp... |
DB11986 | DB12130 | 484 | 1,017 | [
"DDInter648",
"DDInter1094"
] | Entrectinib | Lorlatinib | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
484,
25,
1017
]
],
[
[
484,
63,
1612
],
[
1612,
23,
1017
]
],
[
[
484,
62,
271
],
[
271,
23,
1017
]
],
[
[
484,
63,
786
],
[
786,
... | [
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostems... | Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabe... |
DB06448 | DB11978 | 171 | 124 | [
"DDInter1087",
"DDInter822"
] | Lonafarnib | Glasdegib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
171,
25,
124
]
],
[
[
171,
25,
1135
],
[
1135,
23,
124
]
],
[
[
171,
63,
112
],
[
112,
23,
124
]
],
[
[
171,
24,
466
],
[
466,
6... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause... |
DB01181 | DB09118 | 1,532 | 1,580 | [
"DDInter906",
"DDInter1711"
] | Ifosfamide | Stiripentol | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1532,
24,
1580
]
],
[
[
1532,
63,
473
],
[
473,
24,
1580
]
],
[
[
1532,
24,
407
],
[
407,
63,
1580
]
],
[
[
1532,
24,
98
],
[
98,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium ma... |
DB00812 | DB11718 | 998 | 927 | [
"DDInter1451",
"DDInter640"
] | Phenylbutazone | Encorafenib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
998,
24,
927
]
],
[
[
998,
63,
372
],
[
372,
24,
927
]
],
[
[
998,
24,
1491
],
[
1491,
24,
927
]
],
[
[
998,
24,
484
],
[
484,
6... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Midostauri... |
DB01182 | DB11967 | 371 | 710 | [
"DDInter1534",
"DDInter210"
] | Propafenone | Binimetinib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
371,
24,
710
]
],
[
[
371,
25,
1593
],
[
1593,
24,
710
]
],
[
[
371,
63,
1557
],
[
1557,
24,
710
]
],
[
[
371,
24,
1362
],
[
1362,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizoti... | Propafenone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may cau... |
DB04845 | DB12825 | 309 | 1,375 | [
"DDInter1001",
"DDInter1032"
] | Ixabepilone | Lefamulin | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
309,
24,
1375
]
],
[
[
309,
63,
112
],
[
112,
23,
1375
]
],
[
[
309,
24,
159
],
[
159,
63,
1375
]
],
[
[
309,
25,
976
],
[
976,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib an... |
DB00861 | DB08880 | 914 | 1,510 | [
"DDInter551",
"DDInter1771"
] | Diflunisal | Teriflunomide | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
914,
25,
1510
]
],
[
[
914,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
914,
24,
473
],
[
473,
24,
1510
]
],
[
[
914,
64,
126
],
[
126,
... | [
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nategl... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and ... |
DB00176 | DB00281 | 529 | 608 | [
"DDInter770",
"DDInter1066"
] | Fluvoxamine | Lidocaine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Moderate | 1 | [
[
[
529,
24,
608
]
],
[
[
529,
6,
6017
],
[
6017,
45,
608
]
],
[
[
529,
21,
28722
],
[
28722,
60,
608
]
],
[
[
529,
24,
1017
],
[
1017,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Fluvoxamine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Lidocaine (Compound)
Fluvoxamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatini... |
DB08903 | DB08916 | 996 | 26 | [
"DDInter170",
"DDInter32"
] | Bedaquiline | Afatinib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
996,
24,
26
]
],
[
[
996,
63,
883
],
[
883,
40,
26
]
],
[
[
996,
21,
28809
],
[
28809,
60,
26
]
],
[
[
996,
25,
124
],
[
124,
63... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Bedaquiline (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Bedaquiline may lead to a major life threatening... |
DB00073 | DB01097 | 1,394 | 1,377 | [
"DDInter1608",
"DDInter1033"
] | Rituximab | Leflunomide | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1394,
25,
1377
]
],
[
[
1394,
23,
1461
],
[
1461,
23,
1377
]
],
[
[
1394,
23,
1193
],
[
1193,
62,
1377
]
],
[
[
1394,
24,
949
],
[
949... | [
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Rituximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc glucon... |
DB00526 | DB11601 | 1,555 | 1,270 | [
"DDInter1355",
"DDInter1889"
] | Oxaliplatin | Tuberculin purified protein derivative | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1555,
24,
1270
]
],
[
[
1555,
24,
350
],
[
350,
24,
1270
]
],
[
[
1555,
25,
869
],
[
869,
24,
1270
]
],
[
[
1555,
64,
1064
],
[
1064,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Oxaliplatin may lead to a major life threatening interaction when taken with Topo... |
DB06204 | DB09472 | 768 | 1,383 | [
"DDInter1746",
"DDInter1693"
] | Tapentadol | Sodium sulfate | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
768,
24,
1383
]
],
[
[
768,
63,
1311
],
[
1311,
24,
1383
]
],
[
[
768,
64,
1466
],
[
1466,
24,
1383
]
],
[
[
768,
24,
407
],
[
407,
... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Tapentadol may lead to a major life threatening interaction when taken with Phenylpropanolamine and ... |
DB01259 | DB05528 | 392 | 1,070 | [
"DDInter1024",
"DDInter1228"
] | Lapatinib | Mipomersen | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
392,
25,
1070
]
],
[
[
392,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
392,
25,
1250
],
[
1250,
64,
1070
]
],
[
[
392,
24,
1320
],
[
1320,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Lapatinib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may lead to a major life thre... |
DB00554 | DB09133 | 1,027 | 1,527 | [
"DDInter1478",
"DDInter965"
] | Piroxicam | Iothalamic acid | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
1027,
25,
1527
]
],
[
[
1027,
63,
91
],
[
91,
25,
1527
]
],
[
[
1027,
24,
1512
],
[
1512,
25,
1527
]
],
[
[
1027,
40,
1171
],
[
1171,
... | [
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomy... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may lead to a major life threatening interaction when taken with Iothalamic acid
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lea... |
DB00738 | DB04868 | 485 | 478 | [
"DDInter1420",
"DDInter1293"
] | Pentamidine | Nilotinib | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
485,
25,
478
]
],
[
[
485,
6,
8374
],
[
8374,
45,
478
]
],
[
[
485,
7,
3361
],
[
3361,
46,
478
]
],
[
[
485,
18,
2592
],
[
2592,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Pentamidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Niloti... | Pentamidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Pentamidine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Nilotinib (Compound)
Pentamidine (Compound) downregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Nilotinib (Compound)
Pentamidine (Com... |
DB00245 | DB00981 | 357 | 1,528 | [
"DDInter181",
"DDInter1462"
] | Benzatropine | Physostigmine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
357,
24,
1528
]
],
[
[
357,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
357,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
357,
24,
543
],
[
543,
... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Benzatropine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is... | Benzatropine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00022 | DB09570 | 268 | 1,480 | [
"DDInter1408",
"DDInter1002"
] | Peginterferon alfa-2b | Ixazomib | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
268,
24,
1480
]
],
[
[
268,
24,
440
],
[
440,
24,
1480
]
],
[
[
268,
24,
148
],
[
148,
63,
1480
]
],
[
[
268,
25,
139
],
[
139,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgras... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB08820 | DB08880 | 1,478 | 1,510 | [
"DDInter997",
"DDInter1771"
] | Ivacaftor | Teriflunomide | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1478,
25,
1510
]
],
[
[
1478,
63,
608
],
[
608,
23,
1510
]
],
[
[
1478,
25,
129
],
[
129,
63,
1510
]
],
[
[
1478,
24,
1033
],
[
1033,
... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine"... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ivacaftor may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause... |
DB00682 | DB03619 | 126 | 557 | [
"DDInter1951",
"DDInter501"
] | Warfarin | Deoxycholic acid | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Moderate | 1 | [
[
[
126,
24,
557
]
],
[
[
126,
25,
1479
],
[
1479,
24,
557
]
],
[
[
126,
25,
405
],
[
405,
63,
557
]
],
[
[
126,
64,
1172
],
[
1172,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
... | Warfarin may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid
Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutin... |
DB00687 | DB06655 | 870 | 5 | [
"DDInter747",
"DDInter1077"
] | Fludrocortisone | Liraglutide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
870,
24,
5
]
],
[
[
870,
1,
1103
],
[
1103,
23,
5
]
],
[
[
870,
24,
743
],
[
743,
23,
5
]
],
[
[
870,
63,
1252
],
[
1252,
23,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may caus... | Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that... |
DB01181 | DB08815 | 1,532 | 154 | [
"DDInter906",
"DDInter1104"
] | Ifosfamide | Lurasidone | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1532,
24,
154
]
],
[
[
1532,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1532,
21,
29402
],
[
29402,
60,
154
]
],
[
[
1532,
24,
1033
],
[
1033... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Ifosfamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Ifosfamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Ifosfamide (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00939 | DB09054 | 1,338 | 384 | [
"DDInter1135",
"DDInter905"
] | Meclofenamic acid | Idelalisib | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1338,
24,
384
]
],
[
[
1338,
24,
222
],
[
222,
23,
384
]
],
[
[
1338,
25,
1618
],
[
1618,
24,
384
]
],
[
[
1338,
63,
305
],
[
305,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Meclofenamic acid may lead to a major life threatening interaction when taken with Cabozantinib and Caboz... |
DB00448 | DB11613 | 1,215 | 1,519 | [
"DDInter1022",
"DDInter1924"
] | Lansoprazole | Velpatasvir | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Major | 2 | [
[
[
1215,
25,
1519
]
],
[
[
1215,
24,
594
],
[
594,
24,
1519
]
],
[
[
1215,
40,
379
],
[
379,
25,
1519
]
],
[
[
1215,
24,
129
],
[
129,
... | [
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosuti... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Lansoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening i... |
DB00590 | DB00635 | 1,433 | 1,573 | [
"DDInter592",
"DDInter1515"
] | Doxazosin | Prednisone | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1433,
24,
1573
]
],
[
[
1433,
24,
175
],
[
175,
40,
1573
]
],
[
[
1433,
63,
251
],
[
251,
1,
1573
]
],
[
[
1433,
24,
167
],
[
167,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB00968 | DB09038 | 1,551 | 1,450 | [
"DDInter1185",
"DDInter636"
] | Methyldopa | Empagliflozin | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1551,
24,
1450
]
],
[
[
1551,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1551,
24,
885
],
[
885,
24,
1450
]
],
[
[
1551,
62,
245
],
[
245,
... | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol a... |
DB00981 | DB11181 | 1,528 | 1,590 | [
"DDInter1462",
"DDInter866"
] | Physostigmine | Homatropine (ophthalmic) | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate is a tropane alkaloid. | Moderate | 1 | [
[
[
1528,
24,
1590
]
],
[
[
1528,
24,
61
],
[
61,
40,
1636
],
[
1636,
24,
1590
]
],
[
[
1528,
21,
28653
],
[
28653,
60,
1636
],
[
1636,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Homatropine"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Homatropine
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a moderate interac... |
DB01098 | DB13873 | 14 | 1,534 | [
"DDInter1622",
"DDInter719"
] | Rosuvastatin | Fenofibric acid | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Major | 2 | [
[
[
14,
25,
1534
]
],
[
[
14,
63,
267
],
[
267,
24,
1534
]
],
[
[
14,
24,
1613
],
[
1613,
24,
1534
]
],
[
[
14,
63,
126
],
[
126,
25... | [
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"N... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterfero... |
DB04908 | DB08820 | 1,671 | 1,478 | [
"DDInter741",
"DDInter997"
] | Flibanserin | Ivacaftor | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1671,
24,
1478
]
],
[
[
1671,
23,
1135
],
[
1135,
62,
1478
]
],
[
[
1671,
64,
543
],
[
543,
24,
1478
]
],
[
[
1671,
63,
303
],
[
303,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Flibanserin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Flibanserin may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a mod... |
DB00697 | DB00983 | 876 | 480 | [
"DDInter1821",
"DDInter776"
] | Tizanidine | Formoterol | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
876,
24,
480
]
],
[
[
876,
24,
1148
],
[
1148,
63,
480
]
],
[
[
876,
21,
28963
],
[
28963,
60,
480
]
],
[
[
876,
25,
868
],
[
868,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Tizanidine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Formoterol (Compou... |
DB00196 | DB12301 | 600 | 907 | [
"DDInter743",
"DDInter585"
] | Fluconazole | Doravirine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
600,
23,
907
]
],
[
[
600,
25,
1478
],
[
1478,
23,
907
]
],
[
[
600,
24,
159
],
[
159,
62,
907
]
],
[
[
600,
24,
1213
],
[
1213,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",... | Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may ca... |
DB00556 | DB08868 | 1,262 | 1,011 | [
"DDInter1429",
"DDInter737"
] | Perflutren | Fingolimod | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1262,
25,
1011
]
],
[
[
1262,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1262,
23,
112
],
[
112,
23,
1011
]
],
[
[
1262,
24,
144
],
[
144... | [
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by... | Perflutren (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken ... |
DB00373 | DB01284 | 461 | 1,042 | [
"DDInter1809",
"DDInter1782"
] | Timolol | Tetracosactide | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
461,
24,
1042
]
],
[
[
461,
25,
455
],
[
455,
23,
1042
]
],
[
[
461,
24,
1148
],
[
1148,
23,
1042
]
],
[
[
461,
25,
659
],
[
659,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",... | Timolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause ... |
DB01032 | DB01067 | 824 | 959 | [
"DDInter1522",
"DDInter826"
] | Probenecid | Glipizide | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
824,
24,
959
]
],
[
[
824,
40,
1036
],
[
1036,
1,
959
]
],
[
[
824,
63,
245
],
[
245,
40,
959
]
],
[
[
824,
24,
1411
],
[
1411,
... | [
[
[
"Probenecid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Probenecid",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) r... | Probenecid (Compound) resembles Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Glipizide (Compound)
Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Probenecid may cause a moderate interact... |
DB01319 | DB14723 | 34 | 159 | [
"DDInter777",
"DDInter1026"
] | Fosamprenavir | Larotrectinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
34,
25,
159
]
],
[
[
34,
23,
466
],
[
466,
23,
159
]
],
[
[
34,
25,
1135
],
[
1135,
23,
159
]
],
[
[
34,
24,
98
],
[
98,
24,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"D... | Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Fosamprenavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may... |
DB09030 | DB11166 | 840 | 18 | [
"DDInter1945",
"DDInter104"
] | Vorapaxar | Antithrombin Alfa | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Major | 2 | [
[
[
840,
25,
18
]
],
[
[
840,
63,
1595
],
[
1595,
24,
18
]
],
[
[
840,
64,
848
],
[
848,
24,
18
]
],
[
[
840,
24,
738
],
[
738,
63,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"... | Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Vorapaxar may lead to a major life threatening interac... |
DB06317 | DB06674 | 1,626 | 908 | [
"DDInter630",
"DDInter837"
] | Elotuzumab | Golimumab | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1626,
25,
908
]
],
[
[
1626,
63,
268
],
[
268,
24,
908
]
],
[
[
1626,
24,
505
],
[
505,
63,
908
]
],
[
[
1626,
24,
1136
],
[
1136,
... | [
[
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00757 | DB00918 | 1,166 | 1,373 | [
"DDInter581",
"DDInter49"
] | Dolasetron | Almotriptan | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that ... | Major | 2 | [
[
[
1166,
25,
1373
]
],
[
[
1166,
64,
767
],
[
767,
1,
1373
]
],
[
[
1166,
25,
1541
],
[
1541,
40,
1373
]
],
[
[
1166,
64,
399
],
[
399,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Almotriptan"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zolmitriptan"
],
[
"Zolmitriptan",
"... | Dolasetron may lead to a major life threatening interaction when taken with Zolmitriptan and Zolmitriptan (Compound) resembles Almotriptan (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Naratriptan and Naratriptan (Compound) resembles Almotriptan (Compound)
Dolasetron may lead to... |
DB01197 | DB09154 | 1,603 | 1,475 | [
"DDInter292",
"DDInter1686"
] | Captopril | Sodium citrate | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
1603,
23,
1475
]
],
[
[
1603,
40,
610
],
[
610,
23,
1475
]
],
[
[
1603,
63,
1411
],
[
1411,
23,
1475
]
],
[
[
1603,
63,
1479
],
[
1479... | [
[
[
"Captopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Captopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor int... | Captopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limi... |
DB00284 | DB00363 | 1,647 | 695 | [
"DDInter11",
"DDInter419"
] | Acarbose | Clozapine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Moderate | 1 | [
[
[
1647,
24,
695
]
],
[
[
1647,
24,
1178
],
[
1178,
1,
695
]
],
[
[
1647,
24,
623
],
[
623,
40,
695
]
],
[
[
1647,
24,
104
],
[
104,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Clozapine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Clozapine (Compou... |
DB04868 | DB08938 | 478 | 1,384 | [
"DDInter1293",
"DDInter1112"
] | Nilotinib | Magaldrate | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
478,
24,
1384
]
],
[
[
478,
63,
167
],
[
167,
23,
1384
]
],
[
[
478,
64,
1178
],
[
1178,
23,
1384
]
],
[
[
478,
24,
263
],
[
263,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Nilotinib may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperaz... |
DB09082 | DB11853 | 659 | 230 | [
"DDInter1934",
"DDInter1577"
] | Vilanterol | Relugolix | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
659,
24,
230
]
],
[
[
659,
63,
129
],
[
129,
23,
230
]
],
[
[
659,
63,
480
],
[
480,
24,
230
]
],
[
[
659,
24,
1297
],
[
1297,
2... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formo... |
DB00722 | DB01050 | 743 | 848 | [
"DDInter1079",
"DDInter900"
] | Lisinopril | Ibuprofen | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
743,
24,
848
]
],
[
[
743,
24,
1053
],
[
1053,
1,
848
]
],
[
[
743,
6,
4973
],
[
4973,
45,
848
]
],
[
[
743,
21,
28773
],
[
28773,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Lisinopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ibuprofen (Compound)
Lisinopril (Compound) causes Urethral disorder (Side Effect) and U... |
DB00197 | DB00635 | 1,324 | 1,573 | [
"DDInter1881",
"DDInter1515"
] | Troglitazone | Prednisone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1324,
24,
1573
]
],
[
[
1324,
24,
175
],
[
175,
40,
1573
]
],
[
[
1324,
24,
1547
],
[
1547,
1,
1573
]
],
[
[
1324,
23,
1103
],
[
1103,... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane (Compound) resembles Prednisone (... |
DB01254 | DB01268 | 1,213 | 1,151 | [
"DDInter484",
"DDInter1731"
] | Dasatinib | Sunitinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1213,
24,
1151
]
],
[
[
1213,
6,
2544
],
[
2544,
45,
1151
]
],
[
[
1213,
18,
2284
],
[
2284,
45,
1151
]
],
[
[
1213,
34,
6732
],
[
673... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"JAK2"
],
[
"JAK2",
"{u} (Gene) is bound by {v} (Compound)",
... | Dasatinib (Compound) binds JAK2 (Gene) and JAK2 (Gene) is bound by Sunitinib (Compound)
Dasatinib (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is bound by Sunitinib (Compound)
Dasatinib (Compound) binds MAP2K5 (Gene) and Dasatinib (Compound) upregulates MAP2K5 (Gene) and MAP2K5 (Gene) is bound by Sunitinib (C... |
DB03904 | DB09112 | 1,574 | 1,455 | [
"DDInter1903",
"DDInter1306"
] | Urea | Nitrous acid | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1574,
24,
1455
]
],
[
[
1574,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1574,
63,
572
],
[
572,
24,
1455
]
],
[
[
1574,
24,
433
],
[
433,
... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Em... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Urea may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam and Fenoldopam... |
DB00813 | DB01114 | 704 | 272 | [
"DDInter722",
"DDInter362"
] | Fentanyl | Chlorpheniramine | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
704,
24,
272
]
],
[
[
704,
24,
849
],
[
849,
63,
272
]
],
[
[
704,
1,
11407
],
[
11407,
1,
272
]
],
[
[
704,
63,
128
],
[
128,
2... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Fentanyl (Compound) resembles Bepotastine (Compound) and Bepotastine (Compound) resembles Chlorpheniramine (... |
DB01452 | DB01501 | 993 | 1,118 | [
"DDInter532",
"DDInter549"
] | Diamorphine | Difenoxin | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
993,
24,
1118
]
],
[
[
993,
63,
1688
],
[
1688,
40,
1118
]
],
[
[
993,
6,
6591
],
[
6591,
45,
1118
]
],
[
[
993,
63,
506
],
[
506,
... | [
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
... | Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Diamorphine (Compound) binds OPRM1 (Gene) and OPRM1 (Gene) is bound by Difenoxin (Compound)
Diamorphine may cause a moderate interaction that could exacer... |
DB00035 | DB00180 | 1,314 | 1,351 | [
"DDInter507",
"DDInter749"
] | Desmopressin | Flunisolide | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Major | 2 | [
[
[
1314,
25,
1351
]
],
[
[
1314,
25,
617
],
[
617,
40,
1351
]
],
[
[
1314,
25,
1573
],
[
1573,
1,
1351
]
],
[
[
1314,
21,
28644
],
[
2864... | [
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flunisolide"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"... | Desmopressin may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Flunisolide (Compound)
Desmopressin may lead to a major life threatening interaction when taken with Prednisone and Prednisone (Compound) resembles Flunisolide (Compound)
Desmopressin (Compound) ... |
DB01599 | DB11901 | 1,232 | 913 | [
"DDInter1523",
"DDInter107"
] | Probucol | Apalutamide | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1232,
24,
913
]
],
[
[
1232,
62,
112
],
[
112,
23,
913
]
],
[
[
1232,
63,
600
],
[
600,
24,
913
]
],
[
[
1232,
24,
28
],
[
28,
2... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucon... |
DB00818 | DB12141 | 898 | 971 | [
"DDInter1538",
"DDInter817"
] | Propofol | Gilteritinib | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
898,
24,
971
]
],
[
[
898,
23,
112
],
[
112,
23,
971
]
],
[
[
898,
63,
485
],
[
485,
24,
971
]
],
[
[
898,
24,
823
],
[
823,
63,... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Penta... |
DB09331 | DB14711 | 745 | 779 | [
"DDInter478",
"DDInter1680"
] | Daratumumab | Smallpox (Vaccinia) Vaccine, Live | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
745,
25,
779
]
],
[
[
745,
64,
1064
],
[
1064,
25,
779
]
],
[
[
745,
25,
1259
],
[
1259,
25,
779
]
],
[
[
745,
24,
270
],
[
270,
... | [
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Daratumumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Daratumumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a... |
DB00215 | DB09330 | 1,230 | 985 | [
"DDInter388",
"DDInter1352"
] | Citalopram | Osimertinib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1230,
25,
985
]
],
[
[
1230,
62,
168
],
[
168,
23,
985
]
],
[
[
1230,
23,
112
],
[
112,
23,
985
]
],
[
[
1230,
23,
1478
],
[
1478,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib"... | Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB00356 | DB01142 | 1,315 | 1,264 | [
"DDInter366",
"DDInter593"
] | Chlorzoxazone | Doxepin | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1315,
24,
1264
]
],
[
[
1315,
24,
401
],
[
401,
24,
1264
]
],
[
[
1315,
24,
649
],
[
649,
63,
1264
]
],
[
[
1315,
6,
8374
],
[
8374,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB06616 | DB09154 | 594 | 1,475 | [
"DDInter224",
"DDInter1686"
] | Bosutinib | Sodium citrate | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
594,
24,
1475
]
],
[
[
594,
63,
355
],
[
355,
23,
1475
]
],
[
[
594,
24,
1468
],
[
1468,
23,
1475
]
],
[
[
594,
24,
1406
],
[
1406,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.